Sign In
Buy CAPR
$25.33
-0.680 (-2.61%)
At Close: Jun 10, 2026
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Capricor Therapeutics, Inc. - CAPR
09:00am, Saturday, 24'th May 2025
NEW YORK CITY, NY / ACCESS Newswire / May 24, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Capricor Therapeutics, Inc. ("Capricor" or the "Company") (NASDAQ:CAPR). Such inves
NEW YORK CITY, NY / ACCESS Newswire / May 23, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Capricor Therapeutics, Inc. ("Capricor" or "the Com
Capricor Therapeutics' Buy Thesis Ahead Of Deramiocel PDUFA Date
02:44am, Friday, 23'rd May 2025
Capricor Therapeutics basically has two platforms: Deramiocel CDC therapy and the StealthX exosome platform. However, its flagship candidate is undoubtedly Deramiocel, which has so far secured a PDUFA
NEW YORK CITY, NY / ACCESS Newswire / May 22, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Capricor Therapeutics, Inc. ("Capricor" or "the Com
Capricor: High-Reward DMD Treatment Bet With Strong Data And Looming FDA Decision
12:45am, Thursday, 22'nd May 2025
Capricor's lead asset, deramiocel, targets DMD-related cardiomyopathy and faces key FDA milestones (ADCOM, PDUFA) in 2025. A strong cash position and partnership with Nippon Shinyaku provide financial
NEW YORK CITY, NY / ACCESS Newswire / May 21, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Capricor Therapeutics, Inc. ("Capricor" or "the Com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Capricor Therapeutics, Inc. - CAPR
09:00am, Wednesday, 21'st May 2025
NEW YORK, NY / ACCESS Newswire / May 21, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Capricor Therapeutics, Inc. ("Capricor" or the "Company") (NASDAQ:CAPR). Such investors
Bronstein, Gewirtz & Grossman, LLC Is Investigating Capricor Therapeutics, Inc. (CAPR) And Encourages Stockholders to Connect
10:00am, Tuesday, 20'th May 2025
NEW YORK CITY, NY / ACCESS Newswire / May 20, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Capricor Therapeutics, Inc. ("Capricor" or "the Com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Capricor Therapeutics, Inc. - CAPR
09:00am, Tuesday, 20'th May 2025
NEW YORK , May 20, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Capricor Therapeutics, Inc. ("Capricor" or the "Company") (NASDAQ: CAPR). Such investors are
I Missed The Quantum Rally - I Won't Miss The Next One
05:47am, Tuesday, 20'th May 2025
Here's the next batch of weird science stocks that have market darling potential. I'm tracking five meme-worthy, deep science sectors: brain-computer interfaces, CRISPR/gene editing, organoids, progra
CAPR Investors Have Opportunity to Join Capricor Therapeutics, Inc. Fraud Investigation with the Schall Law Firm
05:26am, Tuesday, 20'th May 2025
LOS ANGELES , May 20, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Capricor Therapeutic
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Capricor Therapeutics, Inc. - CAPR
12:45pm, Monday, 19'th May 2025
NEW YORK, NY / ACCESS Newswire / May 19, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Capricor Therapeutics, Inc. ("Capricor" or the "Company") (NASDAQ:CAPR). Such investors
NEW YORK CITY, NY / ACCESS Newswire / May 19, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Capricor Therapeutics, Inc. ("Capricor" or "the Com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Capricor Therapeutics, Inc. - CAPR
10:00am, Sunday, 18'th May 2025
NEW YORK, May 18, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Capricor Therapeutics, Inc. (“Capricor” or the “Company”) (NASDAQ: CAPR). Such invest
CAPR Investors Have Opportunity to Join Capricor Therapeutics, Inc. Fraud Investigation with the Schall Law Firm
06:36pm, Friday, 16'th May 2025
LOS ANGELES--(BUSINESS WIRE)--CAPR Investors Have Opportunity to Join Capricor Therapeutics, Inc. Fraud Investigation with the Schall Law Firm.
